Marker Therapeutics (NASDAQ:MRKR) Upgraded by Zacks Research to “Strong-Buy” Rating

Zacks Research upgraded shares of Marker Therapeutics (NASDAQ:MRKR) from a hold rating to a strong-buy rating in a report published on Tuesday,Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen upgraded Marker Therapeutics to a “sell” rating in a research note on Saturday, August 16th. Three equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Marker Therapeutics currently has an average rating of “Buy” and a consensus target price of $10.25.

Marker Therapeutics Trading Up 7.9%

MRKR stock opened at $1.09 on Tuesday. The business’s fifty day moving average price is $0.97 and its 200 day moving average price is $1.21. Marker Therapeutics has a 12-month low of $0.81 and a 12-month high of $5.95. The company has a market capitalization of $18.17 million, a PE ratio of -0.89 and a beta of 1.47.

Marker Therapeutics (NASDAQ:MRKR) last announced its earnings results on Thursday, November 13th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.57. The company had revenue of $1.23 million during the quarter, compared to analysts’ expectations of $0.72 million. Marker Therapeutics had a negative return on equity of 92.35% and a negative net margin of 304.56%. Research analysts predict that Marker Therapeutics will post -0.65 EPS for the current fiscal year.

Institutional Trading of Marker Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new stake in Marker Therapeutics during the 3rd quarter worth $25,000. Two Sigma Investments LP purchased a new stake in Marker Therapeutics in the third quarter valued at approximately $33,000. Finally, Jane Street Group LLC purchased a new stake in Marker Therapeutics in the second quarter valued at approximately $33,000. Institutional investors and hedge funds own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.